Frontotemporal Dementia Pipeline

DelveInsight’s, “Frontotemporal Dementia - Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Frontotemporal Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Frontotemporal Dementia: Understanding

Frontotemporal Dementia: Overview

Frontotemporal Dementia (FTD) refers to a group related conditions resulting from the progressive degeneration of the frontal and temporal lobes of the brain. These areas of the brain play a significant role in behavior, language and decision-making abilities. FTD is considered a young-onset dementia, occurring between the ages of 45–65 and is the most common dementia in those under 60 years. It displays clinical symptoms that can be mistaken for other dementias or psychiatric disorders. The average time from symptom onset to accurate diagnosis is about 3.6 years. The aggregation of misfolded, dysfunctional proteins in specific brain regions is a common feature across many neurological diseases and acts as a pathologic hallmark. 

 

Frontotemporal dementia has three distinct clinical syndromes based on the underlying pathologic mechanism characterized by intracellular deposition of abnormal proteins aggregates in the frontal and temporal lobes resulting in the degeneration of neurons, microvacuoles formation, and astrocytosis; hence the term frontotemporal lobar degeneration. Abnormal aggregates of transactive DNA-binding protein TDP-43 account for 50% of cases, microtubules-associated tau protein for 45%, and in 5% to 10% cases, tumor-associated protein fused in sarcoma has been found. The abnormal tau protein aggregates have been identified as the main culprit in patients with both sporadic and familial types of FTD except in the svPPA, in which TDP-43 aggregates predominate.

 

There's currently no cure or specific treatment for frontotemporal dementia but medications and lifestyle changes can help relieve the symptoms. Some antidepressants called as selective serotonin reuptake inhibitors (SSRIs) may help control the loss of inhibitions, overeating and compulsive behaviors seen in some people. Antipsychotic medications, such as olanzapine (Zyprexa) or quetiapine (Seroquel), are sometimes used to combat the behavioral problems in it.  

 

"Frontotemporal Dementia- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Frontotemporal Dementia pipeline landscape is provided which includes the disease overview and Frontotemporal Dementia treatment guidelines. The assessment part of the report embraces, in depth Frontotemporal Dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Frontotemporal Dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal Dementia R&D. The therapies under development are focused on novel approaches to treat/improve Frontotemporal Dementia.

 

Frontotemporal Dementia Emerging Drugs Chapters

This segment of the Frontotemporal Dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Frontotemporal Dementia Emerging Drugs

• AL001: Alector/ GSK

Alector Inc. initiated the development of a Sortilin inhibitor AL001 for the treatment of Frontotemporal Dementia. AL001 is a recombinant human anti-human sortilin (SORT1) monoclonal IgG1 developed by Alector in partnership with GSK. It aims to increase the level of progranulin in humans by inhibiting a progranulin degradation mechanism. The antibody received orphan drug designation, fast track designation, and breakthrough designation from the US FDA for the treatment of frontotemporal dementia. In July 2021, GSK and Alector entered into a global collaboration for the development and commercialization of two monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. The company is currently investigating AL001 in Phase III clinical trials for FTD with a C9orf72 mutation and granulin mutation.

 

• TPN-101: Transposon Therapeutics

TPN-101 specifically inhibits the LINE-1 reverse transcriptase that promotes LINE-1 replication. LINE-1 elements are a class of retrotransposable elements that in humans are uniquely capable of replicating and moving to new locations within the genome. When this process becomes dysregulated, LINE-1 reverse transcriptase drives overproduction of LINE-1 DNA, triggering innate immune responses that contribute to neurodegenerative, autoimmune and aging-related disease pathology. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Frontotemporal Dementia. 

 

• AVB-101: AviadoBio

AVB-101 is a potential one-time therapy designed to stop disease progression by delivering a functional copy of the GRN gene to restore appropriate progranulin levels to affected areas of the brain. The drug is delivered using a minimally invasive, stereotactic neurosurgical procedure directly to the part of the brain called the thalamus. The thalamus has extensive connections to other parts of the brain, including the frontal and temporal lobes, which play a critical role in FTD and the symptoms that impact patients and their families. This targeted delivery method aims to safely and effectively cross the blood-brain barrier, delivering targeted treatment directly to the brain to restore progranulin levels in the frontal and temporal cortex where it is needed most, while at the same time minimizing the dose required and thereby limiting any potential systemic exposure. In November 2023, the US Food and Drug Administration (FDA) granted Fast Track designation to AVB-101. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Frontotemporal Dementia.  

 

• PBFT02: Passage Bio

It is a gene therapy product candidate, an AAV1 viral vector to deliver a modified DNA encoding the granulin gene (GRN) to a patient’s cells. The vector will be delivered directly to the cerebrospinal fluid by a single injection to the cisterna magna (ICM injection). The goal of this vector and delivery approach is to provide higher-than-normal levels of the progranulin protein (PGRN) to the CNS to overcome the progranulin deficiency in GRN gene mutation carriers. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Frontotemporal Dementia.

Further product details are provided in the report……..

 

Frontotemporal Dementia: Therapeutic Assessment

This segment of the report provides insights about the different Frontotemporal Dementia drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Frontotemporal Dementia

There are approx. 15+ key companies which are developing the therapies for Frontotemporal Dementia. The companies which have their Frontotemporal Dementia drug candidates in the most advanced stage, i.e. Phase III include, Alector and GSK.

 

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Frontotemporal Dementia: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Frontotemporal Dementia therapeutic drugs key players involved in developing key drugs. 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Frontotemporal Dementia drugs.

 

Frontotemporal Dementia Report Insights

• Frontotemporal Dementia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Frontotemporal Dementia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Frontotemporal Dementia drugs?
• How many Frontotemporal Dementia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Frontotemporal Dementia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Frontotemporal Dementia therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Frontotemporal Dementia and their status?
• What are the key designations that have been granted to the emerging drugs?